HCV-Antikörper bei NANBH-Patienten und HIV-Risikogruppen-Angehörigen (Pilotstudie).

P. Kühnl; M. Roggendorf; W. Stangel; S. Seidl; R. Laufs; W. Sibrowski; K. Bornhövd; S. Polywka; G. Kalmar; F. Deinhardt

HCV-Antikörper bei NANBH-Patienten und HIV-Risikogruppen-Angehörigen (Pilotstudie).

Translated title of the contribution: Hepatitis C antibodies in non-A, non-B hepatitis patients and members of HIV risk groups (pilot study)

P. Kühnl, M. Roggendorf, W. Stangel, S. Seidl, R. Laufs, W. Sibrowski, K. Bornhövd, S. Polywka, G. Kalmar, F. Deinhardt

University Medical Center Hamburg-Eppendorf

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

In a multi-center study sera from NANB-hepatitis (NANBH) patients and members of so-called HIV-risk groups (homosexuals, i.v.-drug abusers, hemophiliacs) were investigated by the recombinant-based HCV-antibody EIA, 74.4% of chronic NANBH-patients and 20% of acute NANBH patients were anti-HCV reactive, 33.3% of HIV-1-positive homosexuals, 43.5% of i.v.-drug abusers and 73.5% of hemophiliacs. The true prevalence of infection remains to be determined by a second, independent (confirmatory) test.

Translated title of the contribution	Hepatitis C antibodies in non-A, non-B hepatitis patients and members of HIV risk groups (pilot study)
Original language	German
Pages (from-to)	30-32
Number of pages	3
Journal	Beitrage zur Infusionstherapie = Contributions to infusion therapy
Volume	26
State	Published - 1990
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{7a18330c2a424fc3be464179e71b5f92,

title = "HCV-Antik{\"o}rper bei NANBH-Patienten und HIV-Risikogruppen-Angeh{\"o}rigen (Pilotstudie).",

abstract = "In a multi-center study sera from NANB-hepatitis (NANBH) patients and members of so-called HIV-risk groups (homosexuals, i.v.-drug abusers, hemophiliacs) were investigated by the recombinant-based HCV-antibody EIA, 74.4% of chronic NANBH-patients and 20% of acute NANBH patients were anti-HCV reactive, 33.3% of HIV-1-positive homosexuals, 43.5% of i.v.-drug abusers and 73.5% of hemophiliacs. The true prevalence of infection remains to be determined by a second, independent (confirmatory) test.",

author = "P. K{\"u}hnl and M. Roggendorf and W. Stangel and S. Seidl and R. Laufs and W. Sibrowski and K. Bornh{\"o}vd and S. Polywka and G. Kalmar and F. Deinhardt",

year = "1990",

language = "Deutsch",

volume = "26",

pages = "30--32",

journal = "Beitrage zur Infusionstherapie = Contributions to infusion therapy",

issn = "1011-6974",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - HCV-Antikörper bei NANBH-Patienten und HIV-Risikogruppen-Angehörigen (Pilotstudie).

AU - Kühnl, P.

AU - Roggendorf, M.

AU - Stangel, W.

AU - Seidl, S.

AU - Laufs, R.

AU - Sibrowski, W.

AU - Bornhövd, K.

AU - Polywka, S.

AU - Kalmar, G.

AU - Deinhardt, F.

PY - 1990

Y1 - 1990

N2 - In a multi-center study sera from NANB-hepatitis (NANBH) patients and members of so-called HIV-risk groups (homosexuals, i.v.-drug abusers, hemophiliacs) were investigated by the recombinant-based HCV-antibody EIA, 74.4% of chronic NANBH-patients and 20% of acute NANBH patients were anti-HCV reactive, 33.3% of HIV-1-positive homosexuals, 43.5% of i.v.-drug abusers and 73.5% of hemophiliacs. The true prevalence of infection remains to be determined by a second, independent (confirmatory) test.

AB - In a multi-center study sera from NANB-hepatitis (NANBH) patients and members of so-called HIV-risk groups (homosexuals, i.v.-drug abusers, hemophiliacs) were investigated by the recombinant-based HCV-antibody EIA, 74.4% of chronic NANBH-patients and 20% of acute NANBH patients were anti-HCV reactive, 33.3% of HIV-1-positive homosexuals, 43.5% of i.v.-drug abusers and 73.5% of hemophiliacs. The true prevalence of infection remains to be determined by a second, independent (confirmatory) test.

UR - http://www.scopus.com/inward/record.url?scp=18344418988&partnerID=8YFLogxK

M3 - Artikel

C2 - 1703858

AN - SCOPUS:18344418988

SN - 1011-6974

VL - 26

SP - 30

EP - 32

JO - Beitrage zur Infusionstherapie = Contributions to infusion therapy

JF - Beitrage zur Infusionstherapie = Contributions to infusion therapy

ER -

HCV-Antikörper bei NANBH-Patienten und HIV-Risikogruppen-Angehörigen (Pilotstudie).

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this